Artia Global Partners »

Dianthus Therapeutics shares owned by Artia Global Partners

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $8.5M 205k 41.21
2025-09-30 $4.3M 109k 39.35

More positions owned by Artia Global Partners

Insmed Com Par $.01 (INSM)
Abivax Sa Sponsored Ads (ABVX)
Argenx Se Sponsored Adr (ARGX)
Eli Lilly & Co. (LLY)
Proshares Tr Ii Ultra Gold (UGL)
Soleno Therapeutics (SLNO)
Viking Therapeutics (VKTX)
Trevi Therapeutics (TRVI)
Uniqure Nv SHS (QURE)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Astrazeneca Sponsored Adr
Cidara Therapeutics Com New (CDTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Ionis Pharmaceuticals (IONS)
Dianthus Therapeutics (DNTH)

View all positions for Artia Global Partners

Top funds holding Dianthus Therapeutics

FMR
RA Capital Management
Wellington Management Company
Octagon Capital Advisors
Fairmount Funds Management
Avidity Partners Management
Vanguard Group
BlackRock
TCG Crossover Management
State Street Corporation
Braidwell
Point72 Asset Management
Citadel Advisors
Marshall Wace
Polar Capital Holdings

View all funds holding Dianthus Therapeutics